GUTS · Fractyl Health, Inc. · Executive Compensation
$0.97
-0.11 (-9.92%)
At close · Nov 19
Return incl. dividend (before tax)
Play latest call
Q3 2026 earnings call transcript
Going-concern doubt
— flagged Nov 12, 2026
Substantial doubt about the company's ability to continue as a going concern.
“As a result, we have concluded that substantial doubt exists about our ability to continue as a going concern for at least one year after the date that these financial statements are issued.”View the 10-Q filed Nov 12, 2026
Market Cap
$12.67M
Shares
13.26M
Volume · Nov 19
223.24K
Avg daily vol (34 sessions)
804.78K
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Harith Rajagopalan | M.D., Ph.D. Chief Executive Officer | $6,414,290 |
| Jay D. Caplan | President and Chief Product Officer | $3,043,034 |
| Sarah Toomey | General Counsel and Corporate Secretary | $2,445,850 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Harith Rajagopalan | M.D., Ph.D. Chief Executive Officer | $4,856,361 |
| Jay D. Caplan | President and Chief Product Officer | $2,198,612 |
| Lisa Davidson | Chief Financial Officer and Treasurer | $1,972,272 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Harith Rajagopalan | M.D., Ph.D. Chief Executive Officer | $3,561,774 |
| Jay D. Caplan | President and Chief Product Officer | $2,873,373 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Michael Wartell | Class III director | Appointed | 2026-11-06 |
| Harith Rajagopalan, M.D., Ph.D. | President | Appointed | 2026-10-22 |
| Jay Caplan | President and Chief Product Officer | Retired | 2026-10-22 |
|
Lisa Davidson
“The Company appreciates the service of Ms. Davidson and her resignation is not the result of any disagreement with the Board or management on any matter, including the Company's operations, policies or practices.”
|
Chief Financial Officer | Resigned | 2026-01-06 |
| Lara Smith Weber | Chief Financial Officer | Appointed | 2026-01-06 |
|
Amy W. Schulman
“Ms. Schulman's resignation was not the result of any dispute or disagreement with the Company or the Board on any matter relating to the Company's operations, policies or practices.”
|
Class I director | Resigned | 2025-09-03 |
| Ian Sheffield | Class II director | Appointed | 2025-09-03 |
| Christopher Thompson, M.D. | Class I director | Appointed | 2025-09-03 |
Leadership
- Harith Rajagopalan CEO, Board Member
- Lara Smith Weber CFO
- Sarah Toomey General Counsel
- Christopher Thompson, M.D. Board Member
- Ian Sheffield Board Member
- Michael Wartell Board Member
Key facts
CIK
1572616
CUSIP
35168W202
13F (30d)
87 filings
72 filers
Visit website
Investor relations